Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
NCT07425899

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Led by AbbVie · Updated on 2026-04-17

32

Participants Needed

1

Research Sites

22 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.

CONDITIONS

Official Title

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Who Can Participate

Age: 18Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Laboratory values meet the criteria specified in the protocol.
  • General good health based on medical history, physical exam, vital signs, laboratory profile, and 12-lead electrocardiogram (ECG).
Not Eligible

You will not qualify if you...

  • History of any significant illness, infection, major febrile illness, hospitalization, or surgery within 30 days prior to first dose.
  • Chronic recurring infection or active viral infection.
  • Consumption of alcohol, grapefruit products, Seville oranges, starfruit products, or quinine/tonic water within 72 hours before study drug administration.
  • Use of tobacco or nicotine-containing products within 90 days prior to first dose.
  • Evidence of dysplasia or history of malignancy except for certain treated skin or cervical cancers.
  • History or evidence of active or latent tuberculosis.
  • Prior exposure to ABBV-722 within 90 days prior to first dose.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Acpru /Id# 279285

Grayslake, Illinois, United States, 60030

Actively Recruiting

Loading map...

Research Team

A

ABBVIE CALL CENTER

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here